SWX:COPNPharmaceuticals
Cosmo Pharmaceuticals (SWX:COPN) Valuation Reassessed After Strong Phase III Alopecia Results And Regulatory Plans
Cosmo (SWX:COPN) is back in focus after reporting 12 month Phase III results for its Clascoterone 5% topical solution in male androgenetic alopecia, highlighting long term safety, ongoing efficacy and preparation for global regulatory filings.
See our latest analysis for Cosmo.
The latest clinical update comes after a mixed period in the market, with a 23.6% 1 month share price return and a 16.99% 3 month decline. Meanwhile, the 1 year total shareholder return sits at 111.93%, suggesting...